1-14 of 14
Susan M. Domchek
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast

Huaizhi Huang, Ronan E. Couch, Rachid Karam, Chunling Hu, Nicholas Boddicker, Eric C. Polley, Jie Na, Christine B. Ambrosone, Song Yao, Amy Trentham-Dietz, A. Heather Eliassen, Kathryn Penney, Kristen Brantley, Clara Bodelon, Lauren R. Teras, James Hodge, Alpa Patel, Christopher A. Haiman, Esther M. John, Susan L. Neuhausen, Elena Martinez, James V. Lacey, Katie M. O’Brien, Dale P. Sandler, Clarice R. Weinberg, Julie R. Palmer, Kimberly A. Bertrand, Celine M. Vachon, Janet E. Olson, Kathryn E. Ruddy, Hoda Anton-Culver, Argyrios Ziogas, David E. Goldgar, Katherine L. Nathanson, Susan M. Domchek, Jeffrey N. Weitzel, Peter Kraft, Jill S. Dolinsky, Tina Pesaran, Marcy E. Richardson, Siddhartha Yadav, Fergus J. Couch
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (1): 130–138.
https://doi.org/10.1158/1078-0432.CCR-24-1884
Published: 06 January 2025
View article titled, Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma <em>In Situ</em> of the Breast
Open the PDF for Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma <em>In Situ</em> of the Breast in another window
Includes: Supplementary data
Journal Articles

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Yvette Drew, Jae-Weon Kim, Richard T. Penson, David M. O'Malley, Christine Parkinson, Patricia Roxburgh, Ruth Plummer, Seock-Ah Im, Martina Imbimbo, Michelle Ferguson, Ora Rosengarten, Neeltje Steeghs, Min Hwan Kim, Einav Gal-Yam, Daliah Tsoref, Jae-Hoon Kim, Benoit You, Maja De Jonge, Roy Lalisang, Eelke Gort, Sara Bastian, Kassondra Meyer, Laura Feeney, Nigel Baker, Mei-Lin Ah-See, Susan M. Domchek, Susana Banerjee, for the MEDIOLA Investigators
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (1): 50–62.
https://doi.org/10.1158/1078-0432.CCR-23-2249
Published: 05 January 2024
View article titled, Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study
Open the PDF for Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study in another window
Includes: Supplementary data
Journal Articles

The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

Timothy J. Brown, Arielle Yablonovitch, Jacob E. Till, Jennifer Yen, Lesli A. Kiedrowski, Ryan Hood, Mark H. O'Hara, Ursina Teitelbaum, Thomas B. Karasic, Charles Schneider, Erica L. Carpenter, Katherine Nathanson, Susan M. Domchek, Kim A. Reiss
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (24): 5207–5216.
https://doi.org/10.1158/1078-0432.CCR-23-1467
Published: 15 December 2023
View article titled, The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib
Open the PDF for The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib in another window
Includes: Supplementary data
Journal Articles

C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

Stephanie L. Wethington, Payal D. Shah, Lainie Martin, Janos L. Tanyi, Nawar Latif, Mark Morgan, Drew A. Torigian, Diego Rodriguez, Simon A. Smith, Emma Dean, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Eric J. Brown, Wei-Ting Hwang, Deborah K. Armstrong, Stephanie Gaillard, Robert Giuntoli, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2800–2807.
https://doi.org/10.1158/1078-0432.CCR-22-2444
Published: 01 August 2023
View article titled, C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer
Open the PDF for C ombination A TR (ceralasertib) and P A R P (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Classification of BRCA2 Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay

Chunling Hu, Lisa R. Susswein, Maegan E. Roberts, Hana Yang, Megan L. Marshall, Susan Hiraki, Windy Berkofsky-Fessler, Sounak Gupta, Wei Shen, Carolyn A. Dunn, Huaizhi Huang, Jie Na, Susan M. Domchek, Siddhartha Yadav, Alvaro N.A. Monteiro, Eric C. Polley, Steven N. Hart, Kathleen S. Hruska, Fergus J. Couch
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3742–3751.
https://doi.org/10.1158/1078-0432.CCR-22-0203
Published: 01 September 2022
View article titled, Classification of <em>BRCA2</em> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay
Open the PDF for Classification of <em>BRCA2</em> Variants of Uncertain Significance (VUS) Using an ACMG/AMP Model Incorporating a Homology-Directed Repair (HDR) Functional Assay in another window
Includes: Supplementary data
Journal Articles

Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer

Payal D. Shah, Haley Zarrin, Stephanie Wethington, Nawar Latif, Lainie Martin, Diego Rodriguez, Katie Elkins, Robert Giuntoli, Robert Burger, Janos Tanyi, Mark Morgan, Susan M. Domchek, Stephanie Gailliard, Deborah K. Armstrong, Fiona Simpkins
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (13_Supplement): A72.
https://doi.org/10.1158/1557-3265.OVCA19-A72
Published: 01 July 2020
View article titled, Abstract A72: Combination ATR and PARP inhibitor (CAPRI) for recurrent, platinum-resistant ovarian cancer
Journal Articles

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer

Adam A. Kraya, Kara N. Maxwell, Bradley Wubbenhorst, Brandon M. Wenz, John Pluta, Andrew J. Rech, Liza M. Dorfman, Nicole Lunceford, Amanda Barrett, Nandita Mitra, Jennifer J.D. Morrissette, Michael Feldman, Anupma Nayak, Susan M. Domchek, Robert H. Vonderheide, Katherine L. Nathanson
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4363–4374.
https://doi.org/10.1158/1078-0432.CCR-18-0468
Published: 15 July 2019
View article titled, Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer
Open the PDF for Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer

Amy S. Clark, Nicholas P. McAndrew, Andrea Troxel, Michael Feldman, Priti Lal, Mark Rosen, Jessica Burrell, Colleen Redlinger, Maryann Gallagher, Angela R. Bradbury, Susan M. Domchek, Kevin R. Fox, Peter J. O'Dwyer, Angela M. DeMichele
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (7): 2072–2079.
https://doi.org/10.1158/1078-0432.CCR-18-0790
Published: 01 April 2019
View article titled, Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Open the PDF for Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors

Rebecca Kristeleit, Geoffrey I. Shapiro, Howard A. Burris, Amit M. Oza, Patricia LoRusso, Manish R. Patel, Susan M. Domchek, Judith Balmaña, Yvette Drew, Lee-may Chen, Tamar Safra, Ana Montes, Heidi Giordano, Lara Maloney, Sandra Goble, Jeff Isaacson, Jim Xiao, Jen Borrow, Lindsey Rolfe, Ronnie Shapira-Frommer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (15): 4095–4106.
https://doi.org/10.1158/1078-0432.CCR-16-2796
Published: 01 August 2017
View article titled, A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <em>BRCA1/2</em>-Mutated Ovarian Carcinoma or Other Solid Tumors
Open the PDF for A Phase I–II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline <em>BRCA1/2</em>-Mutated Ovarian Carcinoma or Other Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Immunotherapy for Breast Cancer: What Are We Missing?

Robert H. Vonderheide, Susan M. Domchek, Amy S. Clark
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11): 2640–2646.
https://doi.org/10.1158/1078-0432.CCR-16-2569
Published: 31 May 2017
View article titled, Immunotherapy for Breast Cancer: What Are We Missing?
Open the PDF for Immunotherapy for Breast Cancer: What Are We Missing? in another window
Journal Articles

Abstract IA3-3: Genetic testing for breast and ovarian cancer: From risk assessment to therapeutic targeting

Susan M. Domchek
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): IA3-3.
https://doi.org/10.1158/1078-0432.TCMUSA10-IA3-3
Published: 02 February 2016
View article titled, Abstract IA3-3: Genetic testing for breast and ovarian cancer: From risk assessment to therapeutic targeting
Journal Articles

Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

Robert H. Vonderheide, Patricia M. LoRusso, Magi Khalil, Elaina M. Gartner, Divis Khaira, Denis Soulieres, Prudence Dorazio, Jennifer A. Trosko, Jens Rüter, Gabriella L. Mariani, Tiziana Usari, Susan M. Domchek
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (13): 3485–3494.
https://doi.org/10.1158/1078-0432.CCR-10-0505
Published: 30 June 2010
View article titled, Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells
Open the PDF for Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells in another window
Includes: Supplementary data
Journal Articles

Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers

Erica L. Carpenter, Rosemarie Mick, Andrew J. Rech, Gregory L. Beatty, Theresa A. Colligon, Myrna R. Rosenfeld, David E. Kaplan, Kyong-Mi Chang, Susan M. Domchek, Peter A. Kanetsky, Leslie A. Fecher, Keith T. Flaherty, Lynn M. Schuchter, Robert H. Vonderheide
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (13): 4277–4287.
https://doi.org/10.1158/1078-0432.CCR-09-0537
Published: 01 July 2009
View article titled, Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers
Open the PDF for Collapse of the CD27+ B-Cell Compartment Associated with Systemic Plasmacytosis in Patients with Advanced Melanoma and Other Cancers in another window
Journal Articles

Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes

Robert H. Vonderheide, Susan M. Domchek, Joachim L. Schultze, Daniel J. George, Kara M. Hoar, Dih-Yih Chen, Katherine F. Stephans, Kenkichi Masutomi, Massimo Loda, Zhinan Xia, Karen S. Anderson, William C. Hahn, Lee M. Nadler
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (3): 828–839.
https://doi.org/10.1158/1078-0432.CCR-0620-3
Published: 10 February 2004
View article titled, Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes
Open the PDF for Vaccination of Cancer Patients Against Telomerase Induces Functional Antitumor CD8+ T Lymphocytes in another window